Background and purpose

Systemic lupus erythematosus (SLE) is heterogeneous. Older American College of Rheumatology (ACR) classification frameworks captured many classic manifestations but were criticized for incomplete coverage of dermatologic and neurologic spectra, evolving serologic practice, and the need to align renal disease assessment with modern laboratory standards. The Systemic Lupus International Collaborating Clinics (SLICC) group therefore derived and validated revised classification criteria intended for research enrollment, epidemiology, and standardized cohorts, not as a substitute for clinical diagnosis.

The 2012 SLICC criteria reorganize lupus manifestations into discrete, explicitly defined items and add an alternate pathway when kidney biopsy demonstrates lupus nephritis in the presence of characteristic autoantibodies. The result is generally higher sensitivity than prior ACR-based rules in scenario-based validation exercises, with trade-offs in specificity that must be interpreted in context.

Classification versus diagnosis

Classification criteria answer whether a patient resembles a reference case population well enough to be counted in a study. Diagnosis is a broader clinical judgment that integrates timing, severity, alternative explanations, treatment response, and longitudinal evolution. A patient may fulfill SLICC criteria yet not warrant an SLE diagnosis at a single encounter, or may be clinically suspected of SLE before criteria are met. The calculator on this site implements the published counting rule only; it does not replace specialist assessment.

Structure of the 2012 rule

SLICC enumerates eleven clinical and six immunologic criteria in the primary publication’s Table 3. Each satisfied item counts once toward the total. Criteria need not be present concurrently; historical features that met definitions when they occurred may count if they are validly attributed to SLE rather than an alternative cause.

A patient is classified as having SLE if either:

• Standard pathway: at least four criteria are met in total, including at least one clinical criterion and at least one immunologic criterion; or
• Renal biopsy pathway: there is biopsy-proven nephritis compatible with SLE together with positive antinuclear antibodies (ANA) or anti–double-stranded DNA (anti-dsDNA), even if fewer than four criteria are met by checklist alone.

The renal biopsy pathway reflects the consensus that immune-complex lupus nephritis, in the presence of hallmark serology, is highly specific for SLE in classification exercises, while simple proteinuria or casts without biopsy remain categorized under the general renal clinical criterion rather than automatically substituting for the biopsy-defined alternate route.

Clinical criteria (overview)

Each item below is intended to be applied with the exclusions named in the original Table 3 (for example, oral ulcers attributed to infection or inflammatory bowel disease should not count).

Cutaneous disease

Acute cutaneous lupus includes several morphologies (including malar rash when not malar discoid, bullous lupus, toxic epidermal necrolysis–like variant, maculopapular and photosensitive rashes) provided features are not better explained by dermatomyositis. Subacute cutaneous lupus is defined by characteristic non-indurated psoriasiform and/or annular–polycyclic lesions that tend to resolve without scarring (though post-inflammatory pigment change or telangiectasia may occur).

Chronic cutaneous lupus encompasses discoid lesions (localized or generalized), hypertrophic or verrucous lupus, lupus panniculitis, mucosal disease, tumid lupus, chilblain lupus, and discoid–lichen planus overlap, among other specified chronic patterns.

Mucosal and hair

Oral ulcers (palate, buccal mucosa, tongue) or nasal ulcers count when not due to vasculitis, Behçet disease, herpetic infection, reactive arthritis, acidic injury, or other named alternatives. Nonscarring alopecia requires diffuse thinning or fragility with visible broken hairs and excludes common mimics such as alopecia areata, drug-induced shedding, iron deficiency, and androgenetic alopecia.

Musculoskeletal and serosal

Synovitis is defined by swelling or effusion involving two or more joints, or alternatively tenderness in two or more joints with at least thirty minutes of morning stiffness—reflecting an inflammatory joint pattern rather than purely mechanical pain. Serositis includes pleuritic pain, effusions, or rubs, and pericardial pain with positional change, effusion, rub, or electrocardiographic pericarditis, after excluding infectious, uremic, and post–myocardial infarction (Dressler) pericarditis among other causes.

Renal (non-biopsy criterion)

The renal clinical criterion is met by a urine protein-to-creatinine ratio or twenty-four-hour urine collection equivalent to at least 500 mg protein per twenty-four hours, or by red blood cell casts. This is distinct from the stand-alone biopsy pathway, which requires histology compatible with lupus nephritis plus ANA or anti-dsDNA.

Neurologic

Eligible manifestations include seizures, psychosis, mononeuritis multiplex, myelitis, peripheral or cranial neuropathy, and acute confusional state, each with stipulations to exclude primary vasculitis, infection, metabolic encephalopathy, uremia, and medication effects where applicable. The breadth of accepted neurology items addresses important gaps relative to older criteria sets that listed fewer syndromes.

Hematologic

Hemolytic anemia counts as its own item. Leukopenia (<4000 cells/mm³) or lymphopenia (<1000/mm³) on at least one occasion counts when not explained by drugs, portal hypertension, Felty syndrome, corticosteroids, or infection as specified. Thrombocytopenia (<100,000/mm³) at least once counts after excluding drugs, portal hypertension, thrombotic thrombocytopenic purpura, and other listed alternatives.

Immunologic criteria (overview)

Immunologic items emphasize autoantibodies and complement consumption patterns typical of SLE. Assays and reference intervals are laboratory-specific; “positive” always means above the reporting laboratory’s reference unless the criterion specifies a multiplier.

• ANA above the laboratory reference range on HEp-2 or equivalent immunofluorescence (or as validated by local standard).
• Anti-dsDNA above reference; if measured by enzyme-linked immunosorbent assay (ELISA), the original table requires a level twice the upper limit of normal for the assay.
• Anti-Sm positivity.
• Antiphospholipid antibodies: lupus anticoagulant, false-positive rapid plasma reagin (RPR), medium- or high-titer anticardiolipin (immunoglobulin A, G, or M), or anti–β2-glycoprotein I antibodies.
• Low complement: low C3, low C4, or low CH50.
• Direct antiglobulin (Coombs) test positive in the absence of overt hemolytic anemia—this item is logically mutually exclusive with counting hemolytic anemia as the mechanism for a positive Coombs in the same classification pass.

Using the calculator responsibly

Checklist tools reduce arithmetic error but cannot verify whether each manifestation truly meets the published exclusions or whether attribution to SLE is correct. Serologic panels evolve; low-titer or atypical patterns require expert interpretation. Patients with early, organ-threatening disease may need treatment before a full criterion count accrues. Conversely, fulfillment of criteria in isolation should not override a more plausible alternative diagnosis when clinical context strongly suggests it.

For trial eligibility, registries, and observational research, always apply the protocol’s operative definition (which may require additional autoantibody or biopsy rules beyond this calculator) and document source data for each criterion.